Addition of CEA antigen encoding sequence into the viral construct allowed cost efficient and quantitative in vivo monitoring of viral gene expression in tumors of ovarian cancer patients that are negative for the CEA cancer antigen. The gene discussed is CEACAM5; the disease is ovarian cancer.